PsiOxus hires Howard Davis to crack America

PsiOxus, a clinical-stage biotechnology company developing a novel platform technology for the targeted delivery of therapeutic transgenes to solid tumors, has announced the appointment of its new chief executive, Howard Davis (pictured above).

Dr Davis will be based in the greater Boston metropolitan area, where he will establish the company’s US operations. He will replace interim chief executive Priya Mande, who will continue to serve the company in the new role of chief operating officer and UK president.

"Howard is uniquely positioned to lead PsiOxus through its next phase of growth as we establish our US presence to support preparations for late-stage clinical development, expanded partnerships, and USA-focused financing activities"The American brings more than 20 years of experience, having served in diverse roles across vencture capital-backed biotech and large pharma companies spanning a broad range of therapeutic areas including neuroscience, ophthalmology, immunology, and rare diseases. Most recently, Dr Davis worked with venture capital firm Atlas Venture on the launch of Third Harmonic Bio, a clinical stage immunology company where he served as chief operating officer.